Members of the ID Division are involved in a wide array of innovative, interdisciplinary research programs that are dedicated to both advancing knowledge and fostering a culture of excellence in training the next generation of scientific leaders. In fiscal year 2016, the Perelman School of Medicine received $741.6 million in support of its research activities from extramural sponsors, including $392 million from the National Institutes of Health, ranking third in the nation among all academic medical institutions.
Basic and translational research by infectious diseases faculty
As the nation’s first medical school and home to the first teaching hospital, the Perelman School of Medicine has a long tradition of academic excellence and scientific discovery in Basic and Translational Research.
Virology, immunology and vaccines
- Katharine Bar, MD (Basic mechanisms of transmission, pathogenesis and persistence in HIV and other chronic viral infections)
- Harvey Friedman, MD (Herpes virology and herpes simplex vaccine development)
- Stuart Isaacs, MD (Poxvirus therapeutics and vaccines)
- Luis Montaner, DVM, DPhil (HIV-1 immunopathogenesis and new immune-based strategies of anti-HIV therapy)
- Drew Weissman, MD, PhD (novel mRNA platform for vaccines against infectious agents)
- Other virology research lab faculty at Penn
- Other immune response research lab faculty at Penn
- Penn Institute for Immunology faculty
Bacteriology and antibiotics
- Paul Axelsen, MD (antibiotic mechanisms of action)
- Rahul Kohli, MD, PhD (how organisms develop antibiotic resistance; novel antimicrobial development)
- Harvey Rubin, MD, PhD (TB; targeting oxidative phosphorylation in pathogens)
- Other bacteriology research lab faculty at Penn
Microbiome
- Brendan Kelly, MD (Microbial ecology; next-generation sequencing; respiratory tract microbiome; ventilator-associated infection; Clostridium difficile infection)
- Other Microbiome Labs at Penn
Clinical research by infectious diseases faculty
Members of the ID Division are involved in a wide array of innovative, interdisciplinary research programs that are dedicated to both advancing knowledge and fostering a culture of excellence in training the next generation of scientific leaders. In fiscal year 2016, the Perelman School of Medicine received $741.6 million in support of its research activities from extramural sponsors, including $392 million from the National Institutes of Health, ranking third in the nation among all academic medical institutions.
Infection prevention, healthcare-associated infections, antibiotic resistance, and antimicrobial stewardship
- Michael David, MD, PhD (MRSA, healthcare associated infections, antibiotic resistance)
- Kathleen Degnan, MD (Outpatient antibiotic stewardship)
- Lauren Dutcher, MD, MSCE (Antibiotic stewardship interventions, stewardship methods)
- Keith Hamilton, MD, FACP, FSHEA (Healthcare Epidemiology; Antimicrobial Stewardship; Non-tuberculous mycobacterial infections)
- Jerry Jacob, MD, MS (Infections in long-term care facilities)
- Ebbing Lautenbach, MD, MPH, MSCE (antibiotic use, antimicrobial resistance, healthcare-associated infections, epidemiologic methods in the study of infectious diseases)
- Anne Norris, MD (Outpatient Parenteral Antimicrobial Agents, safe and effective transition from hospital to home; use of electronic technologies in healthcare)
- Judith O'Donnell, MD (hospital infection control, epidemiology of healthcare associated infections)
- David Pegues, MD (microbiology testing and antimicrobial therapy, strategies to reduce environmental microbial, epidemiology and prevention of infections in solid organ transplant recipients.
- Naasha Talati, MD, MSCR (latent tuberculosis infection; antimicrobial stewardship)
- Matt Ziegler, MD (Infections in hematologic malignancy patients, environment microbiome)
HIV and HCV
- Val Amorosa, MD (HIV, HCV coinfection)
- Cedric Bien-Gund, MD (Community testing strategies for infectious Diseases, COVID, HIV)
- Greg Bisson, MD, MSCE (Improving treatment outcomes of patients with HIV and tuberculosis and other AIDS-associated opportunistic infections)
- Ian Frank, MD (HIV)
- Robert Gross, MD, MSCE (HIV epidemiology; HIV treatment and adherence)
- Janet Hines, MD (HIV)
- Helen Koenig, MD, MPH (HIV prevention)
- Jessie Torgersen, MD, MHS, MSCE (Viral hepatitis)
- Karam Mounzer, MD (HIV therapy)
- William Short, MD, MPH, MSCE, AAHIVS (HIV)
- Pablo Tebas, MD (HIV, Non-tuberculous mycobacterial infections)
- Jessie Torgersen, MD, MHS, MSCE (HIV-related liver disease, hepatitis)
- Aaron Richterman, MD, MPH (HIV treatment and prevention, socioeconomic interventions)
- Dovie Watson, MD, MSCE, AAHIVS (HIV prevention, sexual and gender minority populations)
Infections in transplantation and cancer
- Emily Blumberg, MD (Infections in transplant recipients)
- Alyssa Mezochow, MD, MSc, MSCE (Impact of Mechanical Circulatory Support and Microbiome Change on Outcomes in Heart Transplant Recipients)
- Mindy Schuster, MD, MSCE (infections in cancer patients; fungal infections)
- Matt Ziegler, MD (Infections in hematologic malignancy patients, environmental microbiome)
Global health
- Greg Bisson, MD, MSCE (Improving treatment outcomes of patients with HIV and tuberculosis and other AIDS-associated opportunistic infections)
- Jennifer Cohn, MD, MPH (International)
- Robert Gross, MD, MSCE (HIV epidemiology; HIV treatment and adherence)
- Ebbing Lautenbach, MD, MPH, MSCE (Antibiotic resistance and antibiotic stewardship in low and middle income countries)
- Carol McLaughlin, MD, MPH, MSCE, DTM&H (Global health, infectious disease epidemiology, community based interventions, impact measurement)
- Botswana UPenn Partnership
- Penn Center for Global Health